Denali develops biological medicines that can reach the brain, mainly for neurodegenerative and rare lysosomal storage diseases. DNLI reports earnings on Tue, Nov 3, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 25 | B. Riley Securities | Maintained | Buy | |
| Aug 7 | UBS | Maintained | Buy | |
| Jul 23 | Morgan Stanley | Target raised | Buy | |
| Jul 16 | Deutsche Bank | Maintained | Buy | |
| Jul 13 | JP Morgan | Reinstated | Buy |
Seasonality
How DNLI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in DNLI in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DNLI is in one of them and how their past DNLI trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered DNLI in an article yet. Here's the latest on the wider market.
About Denali Therapeutics
Denali is a biotechnology company based in South San Francisco, California, that develops biological medicines for serious diseases. Its TransportVehicle technology is designed to carry large molecule drugs, such as enzymes and antibodies, past the barrier that normally keeps them out of the brain. The company focuses on neurodegenerative conditions and rare lysosomal storage disorders, and its medicines are aimed at patients and the doctors who treat them.
- Headquarters
- South San Francisco, CA